Press Releases

Featured Press Releases

BIO Statement Regarding Nomination of Robert F…

BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…

Learn more

BIO Released the Following Statement After…

“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…

Learn more

BIO Statement on Lawsuit Over 340B Rebates

BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…

Learn more

BIO Welcomes Senate Agreement on GMO Labeling

June 23, 2016

Congress urged to “act immediately” to enact national programWashington, D.C. (June 23, 2016) – Senate leaders announced today an agreement on legislative language aimed at establishing national standards for GMO food labeling and disclosure. …

BIO Strongly Opposes H.R. 5573

June 23, 2016

Bill would undermine critical work of biotechnology companies developing new cures and treatments.BIO SVP for Federal Government Relations released the following statement regarding H.R. 5573 and companion legislation in the Senate, which would…

BIO Statement on House GOP Health Care Plan

June 22, 2016

Plan contains a number of promising proposals to protect patient access, foster medical innovation.Biotechnology Innovation Organization (BIO) President for Advocacy, Law and Public Policy Tom DiLenge released the following statement regarding the…

RFS Policy Instability Continues to Chill Investment in Advanced Biofuels, BIO Says

June 21, 2016

EPA’s new methodology for setting annual RFS volumes continues to chill investment in advanced biofuels, according to a new analysis released today. Investment patterns clearly demonstrate that EPA is sending a sustained market signal that…

The following statement regarding today’s Cuozzo Speed Technologies, LLC v. Lee Supreme Court Decision may be attributed to the Biotechnology Innovation Organization

June 20, 2016

Regrettably, today the Supreme Court missed an opportunity in the case of Cuozzo Speed Technologies, LLC v. Lee to reign in the United States Patent and Trademark Office’s Patent Trial and Appeal Board‘s invalidation of many patents under looser…

The 2016 BIO International Convention Closes in San Francisco - Event Sets New Record for Partnering Meetings

June 15, 2016

35,700 Partnering Meetings Held During the Convention15,937 Industry Leaders Attended World's Largest Biotech Gathering

Missouri Governor Nixon Signs Bill Ensuring Patient Access to Interchangeable Biologic Medicines 

June 8, 2016

BIO and Missouri Biotechnology Association (MOBIO) commend Governor Jay Nixon for signing critical legislation to create a pathway for the substitution of interchangeable biologic medicines.

Virginia Governor Terry McAuliffe Presented 2016 BIO Governor of the Year Award

June 8, 2016

BIO today presented Virginia Governor Terry McAuliffe with its 2016 Governor of the Year award in recognition of his leadership and commitment to strengthening the biosciences industry within Virginia. Governor McAuliffe received the award at the…

New Report Shares Best Practices for the Development of Disease-Specific Patient Preference Studies

June 8, 2016

San Francisco, CA (June 8, 2016) – Today, the Biotechnology Innovation Organization (BIO) and Parent Project Muscular Dystrophy (PPMD) released a new report, “Key Considerations for Developing and Integrating Patient Perspectives in Drug…

New Report Shares Best Practices for the Development of Disease-Specific Patient Preference Studies

June 8, 2016

Today, the Biotechnology Innovation Organization (BIO) and Parent Project Muscular Dystrophy (PPMD) released a new report, “Key Considerations for Developing and Integrating Patient Perspectives in Drug Development: Examination of the Duchenne Case…

Daily News You Can’t Afford to Miss

Read it in under 3 minutes!

The Good Day BIO newsletter is the only daily newsletter at the intersection of biotech, politics, and policy.